Page 2 - ஜிநீவ பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covishield vaccination accepted in Switzerland, 7 EU countries Nearly 95 per cent of people with cancer developed a good immune response to the Covid-19 mRNA vaccines three to four weeks after receiving their second dose, finds a new study co-authored by Indian-origin researchers. The study, published in the journal Cancer Cell, indicated that among the 131 patients studied, 94 per cent developed antibodies to the coronavirus. Seven high-risk patients did not. Russia Coronavirus Vaccine YouTube Grab/Sputnik We could not find any antibodies against the virus in those patients, said researcher Dimpy P. Shah from the University Of Texas Health Science Center at San Antonio.

United statesDimpyp shahDimpy shahPankilk shahTexas health science center at san antonioGeneva university hospitalCancer cellCoronavirus vaccineUniversity of texas health science centerGeneva universityஒன்றுபட்டது மாநிலங்களில்மங்கலான ஷாஜிநீவ பல்கலைக்கழகம் மருத்துவமனைபுற்றுநோய் செல்பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ஆரோக்கியம் அறிவியல் மையம்ஜிநீவ பல்கலைக்கழகம்